Head to Head Survey: ReNeuron Group (OTCMKTS:RNUGF) vs. Carlyle Secured Lending (NASDAQ:CGBD)

Carlyle Secured Lending (NASDAQ:CGBD) and ReNeuron Group (OTCMKTS:RNUGF) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Insider and Institutional Ownership

24.5% of Carlyle Secured Lending shares are owned by institutional investors. 0.6% of Carlyle Secured Lending shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Carlyle Secured Lending and ReNeuron Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlyle Secured Lending	1	1	1	0	2.00
ReNeuron Group	0	0	0	0	0.00

Carlyle Secured Lending currently has a consensus target price of $16.67, suggesting a potential downside of 6.58%. Given Carlyle Secured Lending’s stronger consensus rating and higher probable upside, analysts plainly believe Carlyle Secured Lending is more favorable than ReNeuron Group.

Profitability

This table compares Carlyle Secured Lending and ReNeuron Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Carlyle Secured Lending	40.69%	12.60%	5.77%
ReNeuron Group	N/A	N/A	N/A

Volatility & Risk

Carlyle Secured Lending has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, ReNeuron Group has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500.

Earnings & Valuation

This table compares Carlyle Secured Lending and ReNeuron Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlyle Secured Lending	$241.63 million	3.76	$92.28 million	$1.79	9.97
ReNeuron Group	$640,000.00	0.10	-$6.52 million	N/A	N/A

Carlyle Secured Lending has higher revenue and earnings than ReNeuron Group.

Summary

Carlyle Secured Lending beats ReNeuron Group on 12 of the 12 factors compared between the two stocks.

About Carlyle Secured Lending

Carlyle Secured Lending, Inc. is business development company specializing in first lien debt, senior secured loans, second lien senior secured loan unsecured debt, mezzanine debt and investments in equities. It specializes in directly investing. It specializes in middle market. It targets healthcare and pharmaceutical, aerospace and defense, high tech industries, business services, software, beverage food and tobacco, hotel gamming and leisure, banking finance insurance and in real estate sector. The fund seeks to invest across United States of America, Luxembourg, Cayman Islands, Cyprus, and United Kingdom. It invests in companies with EBITDA between $25 million and $100 million.

About ReNeuron Group

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.